Atara Biotherapeutics
ATRA
84 hedge funds and large institutions have $493M invested in Atara Biotherapeutics in 2017 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 8 closing their positions.
107% more call options, than puts
Call options by funds: $540K | Put options by funds: $261K
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
49% more capital invested
Capital invested by funds: $330M → $493M (+$163M)
48% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 21
0.08% more ownership
Funds ownership: 3.22% → 3.3% (+0.08%)
1% less funds holding
Funds holding: 85 → 84 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$28.4M |
| 2 |
BM
Bridger Management
New York
|
+$10.1M |
| 3 |
RI
RTW Investments
New York
|
+$8.88M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$6.14M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.5M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$6.75M |
| 3 |
SPC
Slate Path Capital
New York
|
-$6.75M |
| 4 |
TA
Teachers Advisors
New York
|
-$1.51M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.25M |
ATRA Hedge Fund Activity: Q1 2017 in Review
84 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2017, worth a combined $493M — up 49% from $330M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ATRA positions and 8 closed out — a net gain of 4 holders — while 31 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $28.4M. The largest seller was Fidelity Investments, cutting an estimated $13.5M.
- 84 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2017, down from 85 in Q4 2016.
- Funds reported $493M of Atara Biotherapeutics stock for Q1 2017, up 49% quarter-over-quarter.
- 12 funds opened new Atara Biotherapeutics positions in Q1 2017 and 8 closed out, a net change of +4 holders.
- The largest Atara Biotherapeutics buyer in Q1 2017 was BlackRock, an estimated $28.4M added.
- The largest Atara Biotherapeutics seller in Q1 2017 was Fidelity Investments, an estimated $13.5M sold.
Based on aggregated 13F filings for Q1 2017.